Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06259669 · ClinicalTrials.gov registry record

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

A clinical trial of Atopic Dermatitis and Pregnancy Related, sponsored by Incyte Corporation.

Recruiting
Registry status
958
Enrollment target
1
Study location

NCT06259669 is a study of Atopic Dermatitis and Pregnancy Related that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 958 participants, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (59% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06259669, a study of Atopic Dermatitis and Pregnancy Related, is actively recruiting participants, sponsored by Incyte Corporation.

RECRUITING
Registry status
958 participants
Enrollment target
1
Study location

Study Summary

This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.

Interventions

  • DRUG Ruxolitinib Cream

Study Locations (1)

North Carolina

  • Syneos Health (remote site) - Morrisville

Trial Details

FieldValue
Enrollment Target 958 participants
Start Date 2023-09-13
Est. Completion 2033-08-01

Sponsor

Incyte Corporation

239 total trials

What the Registry Record Tells You About NCT06259669

The ClinicalTrials.gov registry entry for NCT06259669 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 958 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (59% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib Cream is the first listed.

NCT06259669 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06259669 about?

NCT06259669 is a clinical study titled "Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population". This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream durin...

What is the current status of trial NCT06259669?

This trial is currently recruiting. The enrollment target is 958 participants. The study started on 2023-09-13. Estimated completion is 2033-08-01.

What conditions does trial NCT06259669 study?

This clinical trial studies the following conditions: Atopic Dermatitis, Pregnancy Related.

What interventions are being tested in trial NCT06259669?

The interventions under investigation include: Ruxolitinib Cream (DRUG).

Who is sponsoring clinical trial NCT06259669?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06259669 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.